BoneFDA Approved

Vosoritide (Voxzogo)

Subcutaneous injection (daily)

Overview

A C-type natriuretic peptide (CNP) analog that acts as an agonist at the natriuretic peptide receptor B (NPR-B) on growth plate chondrocytes. Vosoritide counteracts the constitutively activated FGFR3 signaling that suppresses endochondral ossification in achondroplasia.

Mechanism of Action

By stimulating the NPR-B/cGMP/MAPK pathway, it antagonizes the growth-inhibitory FGFR3 signal and restores more normal linear bone growth..

Research Summary & Key Findings

FDA-approved in 2021 for achondroplasia in children 5 years and older with open growth plates. Phase 3 trial demonstrated a sustained increase in annualized growth velocity of 1.57 cm/year vs. placebo over 52 weeks (Savarirayan et al., NEJM, 2020). Five-year extension data showed maintained growth velocity improvement. Well-tolerated with transient injection site reactions and blood pressure decreases as common side effects.

Clinical Status

FDA Approved

Vosoritide (Voxzogo) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

Subcutaneous injection (daily)

Related Peptides in Bone

Find a Provider

Find a verified provider who offers Vosoritide (Voxzogo) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Vosoritide (Voxzogo).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.